The independent source for health policy research, polling, and news.
381-400 of 478 results
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent âunapprovedâ and âmisbrandedâ drugs to U.S. consumers, jeopardizing their safety.
Doctors and patients say theyâre compelled to use off-label meds as research goes unfunded.
High-profile failures of implantable medical devices â such as certain hip joints and pelvic mesh â have prompted the Food and Drug Administration to revise its assessment process.
Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHNâs Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.
The race for the cure to aging sparks hope and hype among top scientists â plus billions of dollars in investment.
The Michigan Democrat chaired the House Energy and Commerce Committee and his impact on health care was immense.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half havenât reached the market.
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHNâs Julie Rovner to discuss these issues and, for âextra credit,â provide their favorite health policy stories of the week. Rovner also interviews KHNâs Jordan Rau about the latest âBill of the Month.â
Critics say patients are often misled by ads that advocate high-priced drugs or genetic tests.
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents â inspection records, recalls, warning letters and lawsuits â reveals how drugs that are poorly manufactured or contaminated can reach consumers.
Medicare and Medicaid are fine, but the food safety component of the Food and Drug Administration and bio-threat surveillance done by the Department of Homeland Security are among the public health functions feeling the pinch.
There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.
Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from âbiosimilars.â Itâs a very different story in Europe.
The new-generation gadget is designed to alert and protect wearers from falls and heart problems, expanding Appleâs target audience beyond the usual, tech-savvy, early adopters to those with older tickers.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
In this episode of KHNâs âWhat the Health?â Mary Agnes Carey of Kaiser Health News, Margot Sanger-Katz of The New York Times, Alice Ollstein of Politico and Anna Edney of Bloomberg News discuss the impact of House Democratic leadership elections and their impact on health policy; as well as efforts by the Trump administration to address high drug prices and ensure the safety of medical devices. Plus, Julie Rovner interviews KHNâs Jay Hancock about the latest âBill of the Month.â
In this episode of KHNâs âWhat the Health?â Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Joanne Kenen of Politico and Anna Edney of Bloomberg News discuss the latest on open enrollment for the Affordable Care Act and Medicare; new moves by the Food and Drug Administration to regulate tobacco and nicotine products; and whether House Democrats will pursue a âMedicare-for-allâ bill in the next Congress. Plus, for extra credit, the panelists recommend their favorite health policy books for your holiday reading and gifting pleasure.
The complete findings of a recent study show the FDA-approved drug Vascepa reduced the likelihood of cardiovascular death, stroke and other heart conditions in some patients. But science didnât find the same promise for over-the-counter fish oil supplements when tested in healthy people.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you donât have to.
© 2026 51ÊÓÆ”